Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Intervention versus conservative treatment strategy in patients with unstable angina or non-ST elevation myocardial infarction (the Third Randomised Intervention Treatment of Angina trials [RITA 3])
Source of recordUK Trials
ISRCTNISRCTN07752711
Date ISRCTN assigned16/11/2001
Local reference number(s)RG/96001
Public titleIntervention versus conservative treatment strategy in patients with unstable angina or non-ST elevation myocardial infarction (the Third Randomised Intervention Treatment of Angina trials [RITA 3])
Scientific title
AcronymRITA 3
Disease/condition/study domainUnstable angina/non-ST elevation myocardial infarction
Study hypothesisCurrent guidelines suggest that, for patients at moderate risk of death from unstable coronary-artery disease, either an interventional strategy (angiography followed by revascularisation) or a conservative strategy (ischaemia-driven or symptom-driven angiography) is appropriate. We aimed to test the hypothesis that an interventional strategy is better than a conservative strategy in such patients.
Design/methodologyRandomised controlled trial
Research ethics reviewMulti-centre national ethics committee approval and local ethics committee approval were obtained.
Countries of trialUnited Kingdom
Participants - inclusion criteriaPatients within 24 hours of an index episode of ischaemic pain at rest or patients will have documented evidence of coronary disease with at least one of:
1. Electrocardiogram (ECG) evidence of myocardial ischaemia
2. Pathological Q waves on an ECG suggesting previous myocardial infarction
3. Arteriographically proven coronary disease on a previous angiogram
Participants - exclusion criteriaAll those with probable evolving myocardial infarction, including those for whom reperfusion therapy was indicated, were ineligible. Those in A1 whom new pathological Q waves developed, or those with creatine kinase or creatine kinase Myocardial Bands (MB) concentrations twice the upper limit of normal before randomisation, were excluded. Also excluded were those with myocardial infarction within the previous month, Percutaneous Coronary Intervention (PCI) in the preceding 12 months, or Coronary Artery Bypass Grafting (CABG) at any time.
Patient information materialPatient information can be found on the website at: http://www.rita3.org.uk/
Anticipated start date12/11/1997
Anticipated end date31/12/2006
Status of trialCompleted
Target number of participants1810
InterventionsAngiography followed by Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) versus conservative management.
Primary outcome measure(s)The co-primary endpoints were a combined rate of death, non-fatal myocardial infarction, or refractory angina at 4 months; and a combined rate of death or non-fatal myocardial infarction at 1 year. Analysis was by intention to treat.
Secondary outcome measure(s)Secondary outcomes included subsequent revascularisation, angina scores, anti-anginal medication, quality-of-life scores, and health-economic evaluations.
Trial websitehttp://www.rita3.org.uk
PublicationsResults in:
1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15351164
2. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16154018
3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15653019
4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16621882
Sources of fundingBritish Heart Foundation (UK) (ref: RG/96001) - plus donation from Aventis to the British Heart Foundation
Sponsor nameBritish Heart Foundation (UK)
Sponsor details14 Fitzhardinge Street
London
United Kingdom
W1H 6DH
Sponsor telephone+44 (0)20 7935 0185
Sponsor fax+44 (0)20 7486 5820
Sponsor emailresearch@bhf.org.uk
Sponsor websitehttp://www.bhf.org.uk
Contact nameProf Keith AA Fox
Contact detailsChancellor's Buiding
49 Little France Crescent
Edinburgh
United Kingdom
EH16 4SB
Contact telephone+44 (0)131 536 2743
Contact fax+44 (0)131 536 2744
Contact emailk.a.a.fox@ed.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN07752711
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central